news
Genzyme receives positive CHMP opinion for LEMTRADA™ in Europe
28 June 2013 | By Sanofi
"Today’s CHMP opinions set the stage for the approval of two important new treatment options..."
List view / Grid view
Multiple sclerosis
news
Effect of Genzyme’s LEMTRADA maintained in patients beyond two-year pivotal MS studies
21 March 2013 | By Sanofi
Results from the first year of the extension study of LEMTRADA™ (alemtuzumab)...
news
Genzyme’s LEMTRADA™ application for MS accepted for review by the FDA
28 January 2013 | By Sanofi
Genzyme also reports very encouraging early launch indicators for AUBAGIO® (teriflunomide) in U.S.
news
Sanofi provides an update on its research & development pipeline
8 January 2013 | By Sanofi
Sanofi will provide an update on its Research & Development (R&D) pipeline...
news
Genzyme announces publication of LEMTRADA (alemtuzumab) pivotal studies in The Lancet
31 October 2012 | By
Significant effects of LEMTRADA™ vs. Rebif ® described in CARE-MS I and CARE-MS II publications...
news
Genzyme to present new data from AUBAGIO® and LEMTRADA(TM) Clinical Development Programs at ECTRIMS
9 October 2012 | By Genzyme
New data from Genzyme’s clinical development programs...
news
Genzyme submits applications to FDA and EMA for approval of LEMTRADA™ (alemtuzumab) for multiple sclerosis
12 June 2012 | By Sanofi
Genzyme is developing LEMTRADA in MS in collaboration with Bayer HealthCare...
news
New analysis of risk stratification for TYSABRI® published in New England Journal of Medicine
18 May 2012 | By Biogen Idec / Elan Corporation plc
Use of biomarker has potential to advance personalised treatment for MS patients...
news
Genzyme demonstrates depth of MS pipeline at AAN with results from Miltiple Sclerosis Phase III trials
20 April 2012 | By Sanofi
Full CARE-MS II results for Alemtuzumab to be unveiled...
article
Discovery and validation of biomarkers for multiple sclerosis
13 December 2011 | By Ole Pless and Sheraz Gul, European ScreeningPort GmbH
Multiple Sclerosis (MS) is an autoimmune disease leading to a chronic inflammation and degeneration of the central nervous system. It is one of the major neurological diseases with approximately 2.5 million suffering patients worldwide. Until now, the underlying mechanisms have not been fully elucidated, but the cause of the disease…
news
Genzyme announces successful Phase III results for Alemtuzumab (LEMTRADA) in multiple sclerosis
14 November 2011 | By Sanofi
The Phase lll CARE-MS ll trial met both of its co-primary endpoints...
news
Alemtuzumab significantly reduces relapses in multiple sclerosis vs interferon beta-1a in a Phase III study
22 October 2011 | By Sanofi
New results from the CARE-MS I trial...
news
Oral BG-12 (Dimethyl Fumarate) significantly reduced multiple sclerosis (MS) relapses and disability progression
21 October 2011 | By Biogen Idec
Phase 3 clinical trial demonstrated significant clinical effects...
news
Sanofi reports positive top-line results from first Phase 3 Study of Alemtuzumab (Lemtrada™)
11 July 2011 | By Sanofi
Sanofi and Genzyme announced positive top-line results...
news
Sanofi-Aventis completes acquisition of Genzyme Corporation
8 April 2011 | By Sanofi-Aventis
Sanofi-aventis has announced that it has completed its acquisition of Genzyme Corporation...
